Jenkins Christopher, Hwang Jennifer H, Kopp Jeffrey B, Winkler Cheryl A, Cho Sung Kweon
Department of Internal Medicine, University of Connecticut Health Center, Farmington, CT, United States.
Department of Internal Medicine, The Hospital of Central Connecticut, New Britain, CT, United States.
Front Pharmacol. 2022 Aug 23;13:925219. doi: 10.3389/fphar.2022.925219. eCollection 2022.
We reviewed all currently available ULT, as well as any medications in development using following databases: United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA), and ClinicalTrials.gov. We identified a total of 36 drugs, including 10 approved drugs, 17 in clinical testing phases, and 9 in preclinical developmental phases. The 26 drugs currently undergoing testing and development include 5 xanthine oxidase inhibitors, 14 uricosurics, 6 recombinant uricases, and one with multiple urate-lowering mechanisms of action. Herein, we reviewed the benefit and risk of each drug summarizing currently available drugs. New trials of uricosuric agents are underway to develop the new indication. New drugs are going on to improve the potency of recombinant uricase and to develop the new route administration of such as oral formulation. This review will provide valuable information on the properties, indications, and limitations of ULTs.
我们使用以下数据库对所有目前可用的尿酸降低疗法（ULT）以及任何正在研发的药物进行了审查：美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）、日本药品和医疗器械管理局（PMDA）以及临床试验.gov。我们总共确定了36种药物，其中包括10种已批准药物、17种处于临床试验阶段的药物以及9种处于临床前研发阶段的药物。目前正在进行测试和研发的26种药物包括5种黄嘌呤氧化酶抑制剂、14种促尿酸排泄药、6种重组尿酸酶以及1种具有多种降低尿酸作用机制的药物。在此，我们总结了目前可用药物，回顾了每种药物的益处和风险。促尿酸排泄剂的新试验正在进行，以开发新的适应症。新药正在不断改进重组尿酸酶的效力，并开发新的给药途径，如口服制剂。本综述将提供有关尿酸降低疗法的特性、适应症和局限性的有价值信息。
